The goal of this clinical trial is to learn about the safety and pharmacokinetics (PK, the
amount of drug in the blood) of a new drug called CDI-988 in healthy volunteers.
The main questions it aims to answer are:
- Are there any side effects of the drug?
- What is the amount of drug that reaches the bloodstream? Participants will be assigned
by chance to take either CDI-988 or placebo by mouth and have physical exams,
electrocardiograms (ECGs), vital signs, and blood tests to look for any side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Cocrystal Pharma, Inc.
Collaborators:
Beyond Drug Development Pty Ltd. Cocrystal Pharma Australia Pty Ltd. Nucleus Network Pty Ltd. Resolutum Global Pty Ltd.